Leal, formerly known as Trialjectory, has established a predictive patient platform that offers to 1) help cancer patients navigate their treatment journey at all stages of the disease, 2) educate patients and their oncologists about all of their treatment options in a timely manner to remove barriers to care in advance and 3) enable the pharmaceutical industry to identify potential patients that could match to their trials in the future.
The European Society For Medical Oncology has formally weighed in on a question that U.S. medical groups have been chipping away at as well: How can we guarantee safe and effective use of artificial intelligence in oncology?
